Clinical Trials Register

Summary
EudraCT Number:	2012-003300-13
Sponsor's Protocol Code Number:	RIT-4/DIV
National Competent Authority:	Italy - Italian Medicines Agency
Clinical Trial Type:	EEA CTA
Trial Status:	Prematurely Ended
Date on which this record was first entered in the EudraCT database:	2013-03-04
Trial results	View results

Index
A. PROTOCOL INFORMATION
B. SPONSOR INFORMATION
C. APPLICANT IDENTIFICATION
D. IMP IDENTIFICATION
D.8 INFORMATION ON PLACEBO
E. GENERAL INFORMATION ON THE TRIAL
F. POPULATION OF TRIAL SUBJECTS
G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
P. END OF TRIAL

Expand All Collapse All

A. Protocol Information

A.1

Member State Concerned

Italy - Italian Medicines Agency

A.2

EudraCT number

2012-003300-13

A.3

Full title of the trial

A randomised, double-blind, double-dummy, multi-centre, comparative parallel-group study to evaluate the eficacy of oral Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs placebo in the treatment of acute uncomplicated diverticulitis

Studio comparativo randomizzato, in doppio cieco, a doppia simulazione, multicentrico, a gruppi paralleli per valutare l'efficacia della somministrazione orale di Rifamycin SV-MMX SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. placebo nel trattamento della diverticolite acuta non complicata

A.3.1

Title of the trial for lay people, in easily understood, i.e. non-technical, language

A comparative study on the efficacy of oral Rifamycin SV-MMX® 400 mg two times daily vs Rifamycin SV-MMX® 600 mg b.i.d. three times daily vs placebo (no active medication) in the treatment of acute uncomplicated diverticulitis (inflammation of protuberances of the bowel mucosa)

Uno studio comparativo sull'efficacia del orale Rifamicina SV-MMX ® 400 mg due volte al giorno vs Rifamicina SV-MMX ® 600 mg bid tre volte al giorno vs placebo (nessun farmaco attivo) nel trattamento della diverticolite acuta complicata (infiammazione delle protuberanze della mucosa intestinale)

A.3.2

Name or abbreviated title of the trial where available

Rifamycin 400 mg b.i.d. vs Rifamycin 600 mg t.i.d. vs placebo in the treatment of diverticulitis

Rifamycin 400 mg b.i.d. Rifamycin vs 600 mg t.i.d. vs placebo nel trattamento della diverticolite

A.4.1

Sponsor's protocol code number

RIT-4/DIV

A.7

Trial is part of a Paediatric Investigation Plan

A.8

EMA Decision number of Paediatric Investigation Plan

B. Sponsor Information
B.Sponsor: 1
B.1.1	Name of Sponsor	Dr. Falk Pharma GmbH
B.1.3.4	Country	Germany
B.3.1 and B.3.2	Status of the sponsor	Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1	Name of organisation providing support	Dr. Falk Pharma GmbH
B.4.2	Country	Germany
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1	Name of organisation	Dr. Falk Pharma GmbH
B.5.2	Functional name of contact point	Dept. of Clin.Res & Development
B.5.3	Address:
B.5.3.1	Street Address	Leinenweberstr. 5
B.5.3.2	Town/ city	Freiburg
B.5.3.3	Post code	79108
B.5.3.4	Country	Germany
B.5.4	Telephone number	+4976115140
B.5.5	Fax number	+497611514377
B.5.6	E-mail	zentrale@drfalkpharma.de

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3	IMP Role	Test
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	No
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	Rifamycin Sv-MMX®
D.3.4	Pharmaceutical form	Tablet
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	RIFAMYCIN SODIUM
D.3.9.1	CAS number	14897-39-3
D.3.9.4	EV Substance Code	SUB10310MIG
D.3.10	Strength
D.3.10.1	Concentration unit	mg milligram(s)
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	200
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	Yes
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	No
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No

D.8 Information on Placebo
D.8 Placebo: 1
D.8.1	Is a Placebo used in this Trial?	Yes
D.8.3	Pharmaceutical form of the placebo	Tablet
D.8.4	Route of administration of the placebo	Oral use

E. General Information on the Trial

E.1 Medical condition or disease under investigation

E.1.1

Medical condition(s) being investigated

Acute uncomplicated diverticulitis

Diverticolite acuta non complicata

E.1.1.1

Medical condition in easily understood language

Acute uncomplicated inflammation of protuberances of the bowel mucosa

Infiammazione acuta non complicata di protuberanze della mucosa intestinale

E.1.1.2

Therapeutic area

Diseases [C] - Digestive System Diseases [C06]

MedDRA Classification

E.1.2 Medical condition or disease under investigation

E.1.2	Version	15.1
E.1.2	Level	LLT
E.1.2	Classification code	10055777
E.1.2	Term	Diverticulitis of colon (without mention of haemorrhage)
E.1.2	System Organ Class	100000004862

E.1.3

Condition being studied is a rare disease

E.2 Objective of the trial

E.2.1

Main objective of the trial

to compare the efficacy of Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifacyn SV-MMX® 600 mg t.i.d. vs. placebo, in patients with acute uncomplicated diverticulitis

confrontare l'efficacia di Rifamicina SV-MMX ® 400 mg bid vs Rifamicina SV-MMX ® 600 mg t.i.d. vs placebo, in pazienti affetti da diverticolite acuta non complicata

E.2.2

Secondary objectives of the trial

To compare the efficacy of Rifamycin SV-MMX® 400 mg b.i.d. vs.
Rifamycin SV-MMX® 600 mg t.i.d. vs. placebo, in patients with acute
uncomplicated diverticulitis

•Valutare il dosaggio ottimale di Rifamycin SV-MMX® per il trattamento della diverticolite acuta non complicata
•Studiare la sicurezza e la tollerabilità di Rifamycin SV-MMX® vs. placebo in termini di eventi avversi e parametri di laboratorio

E.2.3

Trial contains a sub-study

E.3

Principal inclusion criteria

1. Signed informed consent,
2. Men or women between 18 and 80 years of age,
3. Diagnosis of left-sided uncomplicated diverticulitis
4. Conservative therapy/management indicated, no need for surgery or
intervention,

1.Consenso informato firmato,
2.Uomini o donne di età compresa fra 18 e 80 anni
3.Diagnosi di diverticolite non complicata sul lato sinistro,
4.Indicazione di terapia/gestione conservativa, nessuna necessità di intervento chirurgico o procedura invasiva.

E.4

Principal exclusion criteria

1. Existing complications of diverticulitis (diverticulitis with associated
abscess, fistula, obstruction or perforation),
2. Right-sided diverticulitis,
3. Previous colonic surgery (except appendectomy, haemorrhoidectomy,
and endoscopic removal of polyps),
4. Chronic inflammatory bowel disease (such as Crohn`s disease,
ulcerative colitis) or celiac disease,
5. Presence of symptomatic organic disease of the gastrointestinal tract
(with the exception of non-bleeding hemorrhoids or hiatal hernia),
6. Inability to tolerate oral intake.

1.Complicanze della diverticolite in atto (diverticolite associata ad ascesso, fistola, ostruzione o perforazione),
2.Diverticolite del lato destro,
3.Precedente intervento chirurgico al colon (ad eccezione di appendicectomia, emorroidectomia e asportazione endoscopica di polipi),
4.Malattie infiammatorie croniche intestinali (ad es. morbo di Crohn, colite ulcerosa) o malattia celiaca,
5.Presenza di malattie organiche sintomatiche del tratto gastrointestinale (ad eccezione di emorroidi non sanguinanti o ernia iatale),
6.Incapacità di tollerare l'assunzione orale.

E.5 End points

E.5.1

Primary end point(s)

rate of patients with treatment success at the day 10 visit

percentuale di pazienti con il successo del trattamento alla visita nel giorno 10

E.5.1.1

Timepoint(s) of evaluation of this end point

after 10 days of treatment

dopo 10 giorni di trattamento

E.5.2

Secondary end point(s)

· Rate of treatment success at V3 and V4
· First visit with treatment success (V3, V4 or V5)
· Rate of treatment failure at V3, V4 and V5
· First visit with treatment failure (V3, V4 or V5)
· Rate of surgical intervention of acute diverticulitis until V5 and V6
· Rate of antimicrobial treatment due to acute diverticulitis until V5 and
V6
· Rate of hospitalisation due to acute diverticulitis until V5 and V6
· Rate of occurrence of complicated diverticulitis until V5 and V6
· Use of rescue therapy until V5

•Tasso di successo del trattamento alla visita V3 e V4
•Prima visita con successo del trattamento (V3, V4 o V5)
•Tasso di fallimento del trattamento alla visita V3, V4 e V5
•Prima visita con fallimento del trattamento (V3, V4 o V5)
•Tasso di intervento chirurgico per diverticolite acuta fino alla visita V5 e V6
•Tasso di trattamento antimicrobico a causa di diverticolite acuta fino alla visita V5 e V6
•Tasso di ospedalizzazione per diverticolite acuta fino alla visita V5 e V6
•Tasso di insorgenza della diverticolite complicata fino alla visita V5 e V6
•Utilizzo della terapia di salvataggio fino alla visita V5

E.5.2.1

Timepoint(s) of evaluation of this end point

timepoints of evaluation are included in the description of endpoints in E.5.2

timepoints di valutazione sono inclusi nella descrizione di endpoint nella sezione E.5.2

E.6 and E.7 Scope of the trial

E.6

Scope of the trial

E.6.1

Diagnosis

E.6.2

Prophylaxis

E.6.3

Therapy

Yes

E.6.4

Safety

Yes

E.6.5

Efficacy

Yes

E.6.6

Pharmacokinetic

E.6.7

Pharmacodynamic

E.6.8

Bioequivalence

E.6.9

Dose response

Yes

E.6.10

Pharmacogenetic

E.6.11

Pharmacogenomic

E.6.12

Pharmacoeconomic

E.6.13

Others

E.7

Trial type and phase

E.7.1

Human pharmacology (Phase I)

E.7.1.1

First administration to humans

E.7.1.2

Bioequivalence study

E.7.1.3

Other

E.7.1.3.1

Other trial type description

E.7.2

Therapeutic exploratory (Phase II)

Yes

E.7.3

Therapeutic confirmatory (Phase III)

E.7.4

Therapeutic use (Phase IV)

E.8 Design of the trial

E.8.1

Controlled

Yes

E.8.1.1

Randomised

Yes

E.8.1.2

Open

E.8.1.3

Single blind

E.8.1.4

Double blind

Yes

E.8.1.5

Parallel group

Yes

E.8.1.6

Cross over

E.8.1.7

Other

Yes

E.8.1.7.1

Other trial design description

double dummy

E.8.2

Comparator of controlled trial

E.8.2.1

Other medicinal product(s)

E.8.2.2

Placebo

Yes

E.8.2.3

Other

Yes

E.8.2.3.1

Comparator description

Rifamycin SV-MMX® 600 mg t.i.d as comparator to Rifamycin SV-MMX® 400 mg b.i.d.

E.8.2.4

Number of treatment arms in the trial

E.8.3

The trial involves single site in the Member State concerned

E.8.4

The trial involves multiple sites in the Member State concerned

Yes

E.8.4.1

Number of sites anticipated in Member State concerned

E.8.5

The trial involves multiple Member States

Yes

E.8.5.1

Number of sites anticipated in the EEA

E.8.6 Trial involving sites outside the EEA

E.8.6.1

Trial being conducted both within and outside the EEA

E.8.6.2

Trial being conducted completely outside of the EEA

E.8.7

Trial has a data monitoring committee

Yes

E.8.8

Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial

LVLS

E.8.9 Initial estimate of the duration of the trial

E.8.9.1

In the Member State concerned years

E.8.9.1

In the Member State concerned months

E.8.9.1

In the Member State concerned days

E.8.9.2

In all countries concerned by the trial years

E.8.9.2

In all countries concerned by the trial months

F. Population of Trial Subjects

F.1 Age Range

F.1.1

Trial has subjects under 18

F.1.1.1

In Utero

F.1.1.2

Preterm newborn infants (up to gestational age < 37 weeks)

F.1.1.3

Newborns (0-27 days)

F.1.1.4

Infants and toddlers (28 days-23 months)

F.1.1.5

Children (2-11years)

F.1.1.6

Adolescents (12-17 years)

F.1.2

Adults (18-64 years)

Yes

F.1.2.1

Number of subjects for this age range:

187

F.1.3

Elderly (>=65 years)

Yes

F.1.3.1

Number of subjects for this age range:

188

F.2 Gender

F.2.1

Female

Yes

F.2.2

Male

Yes

F.3 Group of trial subjects

F.3.1

Healthy volunteers

F.3.2

Patients

Yes

F.3.3

Specific vulnerable populations

Yes

F.3.3.1

Women of childbearing potential not using contraception

F.3.3.2

Women of child-bearing potential using contraception

Yes

F.3.3.3

Pregnant women

F.3.3.4

Nursing women

F.3.3.5

Emergency situation

F.3.3.6

Subjects incapable of giving consent personally

F.3.3.7

Others

F.4 Planned number of subjects to be included

F.4.1

In the member state

F.4.2

For a multinational trial

F.4.2.1

In the EEA

375

F.4.2.2

In the whole clinical trial

375

F.5

Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)

treatment after study end is left to investigator's discretion

il trattamento a fine studio è lasciato a discrezione dello Sperimentatore

G. Investigator Networks to be involved in the Trial

N. Review by the Competent Authority or Ethics Committee in the country concerned

Competent Authority Decision

Authorised

Date of Competent Authority Decision

2013-03-21

Ethics Committee Opinion of the trial application

Favourable

Ethics Committee Opinion: Reason(s) for unfavourable opinion

Date of Ethics Committee Opinion

2013-03-27

P. End of Trial
P.	End of Trial Status	Prematurely Ended

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials